Automated Detection of Arm-Level Alterations for Individual Cancer Patients
By LabMedica International staff writers Posted on 25 Sep 2021 |
The Quant-iT 1X dsDNA HS (High-Sensitivity) Assay Kit is designed to make DNA quantitation easy and accurate. The assay is highly selective for double-stranded DNA (dsDNA) over RNA (Photo courtesy of Thermo Fisher Scientific)
Copy number alterations (CNAs) can be gains, losses, or loss of heterozygosity (LOH) of a chromosome segment. Based on the length of the altered segment, they are crudely classified as “focal alterations” and “arm-level alterations”.
While genome-wide techniques to detect arm-level alterations are gaining momentum in hospital laboratories, the high precision and novelty of these techniques pose new challenges. There is no consensus on the definition of an arm-level alteration and a lack of tools to compute them for individual patients.
Clinical Scientists at the Geneva University Hospital (Geneva, Switzerland) performed OncoScan FFPE assays (Thermo Fisher Scientific, Waltham, MA, USA) for more than 400 patients as part of the routine laboratory analyses from 2016 to 2018. The median age at the time of analysis was 59 years for females and 60 years for males. Among these 376 samples, 25 were manually selected to validate the method against the expert annotations from the clinical report. Centered on the content of the clinical reports, the selection was made to represent a diverse range of arm-level alterations in terms of chromosomal distribution, CNA type (Gain versus. Loss of copies), tumor ploidy, and the number of arms altered.
Genomic DNA was purified from Formalin-Fixed Paraffin-Embedded (FFPE) tumor tissues using QIAamp DNA FFPE Tissue Kit (QIAGEN (Hilden, Germany) and quantified using the Quant-iT dsDNA HS Assay Kit (Life Technologies, CA, USA). The arrays were stained in GeneChip Fluidics Station (Thermo Fisher Scientific) and scanned using the Gene Chip scanner. The OncoScan assay has a genome-wide resolution of 300Kbp and an even finer 50-100Kbp resolution on ∼ 900 cancer genes.
The team observed a bimodal distribution of the percentage of bases with CNAs within a chromosomal arm, with the second peak starting at 90% of arm length. They tested two approaches for the definition of arm-level alterations: sum of altered segments (SoS) >90% or the longest segment (LS) >90%. The approaches were validated against expert annotation of 25 clinical cases. The SoS method outperformed the LS method with a higher concordance (SoS: 95.2 %, LS: 79.9 %). Some of the discordances were ultimately attributed to human error, highlighting the advantages of automation. The investigators observed that both computational approaches (SoS and LS) showed a high number of arm-level alterations (Gain (27), Loss (14) and LOH (8)), which were missed by the manual annotation, but detected by this approach.
The authors concluded that their computational method is highly accurate and robust for detecting copy number alterations across diverse cancer types in a clinical setting. The method performs as accurately as human experts, but at a fraction of the time. A software tool also increases reliability, as typographic and annotation errors were observed in some manually curated cases. The method and tool they described are now routinely used in the Department of Clinical Pathology at the Geneva University Hospitals and are available to the community. The study was published on August 25, 2021 in The Journal of Molecular Diagnosis.
While genome-wide techniques to detect arm-level alterations are gaining momentum in hospital laboratories, the high precision and novelty of these techniques pose new challenges. There is no consensus on the definition of an arm-level alteration and a lack of tools to compute them for individual patients.
Clinical Scientists at the Geneva University Hospital (Geneva, Switzerland) performed OncoScan FFPE assays (Thermo Fisher Scientific, Waltham, MA, USA) for more than 400 patients as part of the routine laboratory analyses from 2016 to 2018. The median age at the time of analysis was 59 years for females and 60 years for males. Among these 376 samples, 25 were manually selected to validate the method against the expert annotations from the clinical report. Centered on the content of the clinical reports, the selection was made to represent a diverse range of arm-level alterations in terms of chromosomal distribution, CNA type (Gain versus. Loss of copies), tumor ploidy, and the number of arms altered.
Genomic DNA was purified from Formalin-Fixed Paraffin-Embedded (FFPE) tumor tissues using QIAamp DNA FFPE Tissue Kit (QIAGEN (Hilden, Germany) and quantified using the Quant-iT dsDNA HS Assay Kit (Life Technologies, CA, USA). The arrays were stained in GeneChip Fluidics Station (Thermo Fisher Scientific) and scanned using the Gene Chip scanner. The OncoScan assay has a genome-wide resolution of 300Kbp and an even finer 50-100Kbp resolution on ∼ 900 cancer genes.
The team observed a bimodal distribution of the percentage of bases with CNAs within a chromosomal arm, with the second peak starting at 90% of arm length. They tested two approaches for the definition of arm-level alterations: sum of altered segments (SoS) >90% or the longest segment (LS) >90%. The approaches were validated against expert annotation of 25 clinical cases. The SoS method outperformed the LS method with a higher concordance (SoS: 95.2 %, LS: 79.9 %). Some of the discordances were ultimately attributed to human error, highlighting the advantages of automation. The investigators observed that both computational approaches (SoS and LS) showed a high number of arm-level alterations (Gain (27), Loss (14) and LOH (8)), which were missed by the manual annotation, but detected by this approach.
The authors concluded that their computational method is highly accurate and robust for detecting copy number alterations across diverse cancer types in a clinical setting. The method performs as accurately as human experts, but at a fraction of the time. A software tool also increases reliability, as typographic and annotation errors were observed in some manually curated cases. The method and tool they described are now routinely used in the Department of Clinical Pathology at the Geneva University Hospitals and are available to the community. The study was published on August 25, 2021 in The Journal of Molecular Diagnosis.
Related Links:
Geneva University Hospital
Thermo Fisher Scientific
QIAGEN
Life Technologies
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans